Evidence map›Paper›PMID 41200556›Full record

ArticleFrontiers in cellular and infection microbiology2025

Metabolomics reveals the mechanisms of action of fosfomycin and azithromycin combination in the treatment of

Ziyun Zhao, Shuo Diao, Meng Song, Xiujiao Cao, Yiran Zhao, Mingming Yu, Zhihua Lv, Sherwin K B Sy, Hai Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Calcium regulation ofApplied and environmental microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ziyun Zhao *Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Shuo Diao *School of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
Meng SongQingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Xiujiao CaoSchool of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
Yiran ZhaoSchool of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
Mingming YuSchool of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
Zhihua LvSchool of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
Sherwin K B SyDepartment of Statistics, State University of Maringá, Maringá, Paraná, Brazil.
Hai YangQingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Fosfomycin combined with other antibiotics is often used to treat Methods: Multidrug-resistant Results: The minimum inhibitory concentration was 32/4 μg/mL for fosfomycin/azithromycin combination against the Conclusion: Fosfomycin-azithromycin combination therapy exerted stronger interference on the metabolic pathways of

Indexed as

Anti-Bacterial AgentsAzithromycinFosfomycinMetabolomePseudomonas aeruginosaChromatography, LiquidDrug Resistance, Multiple, BacterialDrug Therapy, CombinationHumansMetabolic Networks and PathwaysMetabolomicsMicrobial Sensitivity TestsPseudomonas InfectionsTandem Mass SpectrometryAnti-Bacterial AgentsAzithromycinFosfomycinazithromycincombination therapyfosfomycinmetabolomicsPseudomonas aeruginosa

Identifiers

PMID41200556
PMCPMC12585984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.